Adaptimmune Therapeutics plc

Click here for new animation
<
>

Promising data from Phase 1 Trial with ADP-A2AFP presented at International Liver Congress

Read More
<
>

Adaptimmune Reports Q2 Financial Results and Business Update

Read More
<
>

Adaptimmune granted PRIME regulatory support by EMA for ADP-A2M4 for synovial sarcoma

Read More
<
>

We have been chosen as one of the Best Places to work in Philadelphia

Click Here
<
>

Clinical update at ASCO with new responses in esophagogastric junction (EGJ), lung, and head & neck cancers, and late stage development initiated in EGJ cancer

Read more
<
>

Adaptimmune’s mission is to transform the lives of people with cancer by designing and delivering cell therapies

Learn More
<
>
Our Clinical Trials

Advancing T-cell therapy through world-class expertise

Our main priority at Adaptimmune is to improve the outcomes of patients who are suffering from cancer via immunotherapy.

View Our Clinical Trials
For Patients and Families

Helpful resources for patients and their families

Our efforts in immunotherapy are aimed at improving outcomes for patients who are living with cancer. Our resources are available to both patients their families.

View Our Resources
Our Pipeline

SPEAR-heading the Cancer Revolution

An industry leading TCR pipeline that targets solid tumors

We build affinity-enhanced T-cell therapies aimed at destroying cancer cells. Our therapies work with the immune system to improve the detection and targeting of those cancer cells.

View Our Pipeline

Our Robust Manufacturing Process

Delivering affinity-enhanced TCRs to patients

Our manufacturing process provides world class capabilities for designing and delivering cell which enables us to efficiently supply patients in our clinical trials.

Learn More

Latest News

Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients

Read Press Release View All News

Adaptimmune Reports Q2 Financial Results and Business Update

Read Press Release

Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma

Read Press Release

Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020

Read Press Release